Brodalumab is a fully human anti-IL17 RA antibody that inhibits the biological activity of IL-17A, IL-17F, and other IL-17 family members, and a phase III trial in AS is ongoing (identifier: NCT02985983). Here, IL17A is linked to rheumatoid arthritis.